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It remains a great challenge to treat the complexity of 
systemic rheumatic diseases in clinical practice. In 
contrast to what one may think, these challenges are not 
so much related to a lack of eﬀ  ective treatments, as many 
powerful drugs are available for treating rheumatoid 
arthritis, many of which became licensed over the course 
of the past decade [1]. Th   e use of any of these new - as 
well as of the ‘older’ - drugs is scientiﬁ  cally based on 
results of randomized controlled trials. Th  e classical 
design of these trials, however, is what makes the step 
into clinical practice so challenging. With the strict 
inclusion and exclusion criteria of these trials, the patient 
populations tested in those trials are in sharp contrast to 
patients requiring treatment in clinical practice. Th  is is 
further supported by the fact that only a fraction of 
patients in a rheumatology practice would fulﬁ  ll  the 
criteria to enter phase II/III trials [2]. A central reason for 
this is that patients with potential risk factors for an 
adverse reaction to an investigative drug are excluded 
from the beginning to make the trial safer; but this group 
of patients constitutes a large portion of those who will 
ultimately require treatment in clinical practice. Until the 
recent calls for more pragmatic trials [3] that address 
patient populations with all the risk factors faced in daily 
practice have manifested in actual trial designs, physi-
cians will often need to make their own decisions, 
weighing expected (but sometimes unknown) risks 
against the possible beneﬁ  ts.
Although a number of management guidelines for 
diﬀ   erent rheumatic diseases, such as those by the 
European League Against Rheumatism (EULAR) or the 
American College of Rheumatology (ACR), are in the 
public domain, the guidance is inherently vague when it 
comes to the many diﬀ  erent challenges of dealing with 
comorbid conditions in rheumatic diseases. Th  e main 
concerns here are safety issues associated with treatments, 
such as in the case of nonsteroidal anti-inﬂ  ammatory 
drug (NSAID) treatment in patients with liver or 
cardiovascular disease, but in theory one could also think 
about potential synergisms of treating the index disease 
and a comorbid condition at the same time - for example, 
when treating arthritis patients with concomitant 
inﬂ  ammatory bowel disease.
Th   e purpose of this new series of reviews in Arthritis 
Research and Th  erapy is to comprehensively provide an 
update on these issues, including new developments and 
current perspectives on rheumatic patients who present 
with a comorbid condition. Each review of this series 
therefore addresses a diﬀ  erent organ or organ system. We 
are very grateful that experts specialized in rheumatology 
together with experts from other specialties have contri-
buted to this series by reviewing the currently available 
literature combined with their expertise. Speciﬁ  cally, the 
series will provide a very broad perspective on distinct 
and frequent organ manifestations provided by experi-
enced rheumatologists as well as pulmologists, nephro  lo-
gists, oncologists, hematologists, infecti  ous diseases 
special  ists, and hepatologists, respectively, in each review.
Th   e lack of clear recommendations on how to manage 
most of the comorbid situations, but also the diﬃ   culty of 
ﬁ  nding important data from cohort studies and registries, 
which are usually reported less prominently than clinical 
trials, are a major motivation for this series. Th  e  ﬁ  rst of 
these reviews, which is published in the current issue of 
Arthritis Research and Th  erapy on ‘Treating rheu  matic 
patients with a malignancy’ [4], is exemplary in support-
ing this motivation: malignancy, even ‘just’ by history, is a 
major challenge in real life, as many of the drugs used to 
treat rheumatic diseases are immunosuppressives, and as 
such are often claimed to increase the risk of malignancy, 
even in otherwise healthy individuals.
We hope that the reviews from the current comorbidity 
series will provide a comprehensive and up-to-date over-
view. Each review will allow the reader to gain a 
comprehensive look at the respective clinical question, 
and hopefully help to facilitate daily decisions in clinical 
practice. At the same time, academic centers are working 
on the research agenda to identify and ﬁ  ll gaps in the 
evidence on how to manage comorbidities in certain 
rheumatic diseases. Although these reviews do not  © 2010 BioMed Central Ltd
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